Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Capecitabine, Irinotecan, and Radiotherapy for Rectal Cancer
NCT00972881Phase 2Completed
- Sponsor
- University College London
- Start
- Apr 2009
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in rectal cancer, sponsored by University College London. Started Apr 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00972881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972881.